Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Article content
MONTREAL — Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic.
Article content
Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future.
Article content
'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.'
Article content
Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases.
Article content
'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.'
Article content
About Innospera Pharma
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
As N.S officials discuss $4.5B hospital expansion, CEO says a new one likely needed, too
Karen Oldfield, the interim president and CEO of Nova Scotia Health, speaks to reporters after appearing before the province's public accounts committee where healthcare facilities were top of mind. (CTV Atlantic/Callum Smith) Officials in charge of the $7.4-billion QEII Halifax Infirmary expansion and maintenance project appeared before a legislative committee on Wednesday, offering some details – but not others – about where the project stands and where it's heading. During those discussions though, Karen Oldfield, the interim president and CEO of Nova Scotia Health, said a new hospital may also be required in the coming years. 'I don't want to presuppose an outcome, but I would be shocked if there was not some indication of another major or regional hospital being required in the Central Zone over the course of the planning horizon,' Oldfield said. 'I'm not announcing that, I'm not saying that,' she said. 'I'm intuiting that.' The population growth, particularly in the HRM, 'makes it very necessary to figure out just how we're going to build out the Central Zone,' she continued. But building is only part of the battle. She acknowledged staffing, timing and budgeting are only some components that need to be considered as part of the health authority's master plan. While speaking to reporters, Oldfield said several population factors will put even more pressure on the system. 'We're almost in a race against time to prepare for that peak to have the healthcare facilities ready, to have long-term care facilities ready. 'It's the demographics, it's the age, but it's also the baby boom that's hitting – I think it peaks out at 2035 – where a significant percentage of Nova Scotians are over age 65, and then it comes back down again,' Oldfield said. Acknowledging that a larger percentage of an aging population will likely lead to higher healthcare needs and long-term care needs. Oldfield said when she was appointed to her role by Premier Tim Houston in 2021, Nova Scotia Health did not have a 10-year capital plan, which makes it 'very difficult to plan when you don't have a long-term plan.' Construction update Oldfield said the QEII Halifax Infirmary expansion project's design phase is nearly 75 per cent completed, 'and that work is being shaped by those who use the spaces every day.' The first two cranes arrived last month and two more will arrive later this summer as part of the largest infrastructure project in the province's history. Construction crews started pouring the foundation last month and the concrete structure will rise to the main floor in December, 'marking a significant milestone,' said David Benoit, the CEO of Build Nova Scotia. Benoit reiterated numerous times to the Standing Committee on Public Accounts that the $7.4-billion price tag – including $4.5-billion in construction costs and $2.9-billion for 30-year maintenance costs – is part of a 'firm fixed price and schedule.' 'If things arise, like tariffs or hurricanes, or unexpected, unforeseeable things, there are clauses in the contract which allow for a conversation to happen,' he said. 'I'm comfortable that we got value for money, but you don't have to take my word for it,' Benoit told the committee. He told reporters a long-awaited 'value for money' document will be released to the public, likely within 'days.' When asked how tariffs could impact costs, John Volcko, PCL Constructors vice president of corporate development, said they learned a lot about price volatility and escalation during the COVID-19 pandemic. 'Within our bid, we've got certain allowances, certain contingencies to deal with unexpected things like that,' he told reporters. Interim Liberal leader Derek Mombourquette asked that the contract between the province and Plenary PCL Health (PPH) be tabled at the committee. The expansion will see a new, modern, 14-floor acute care tower with 216 beds, 16 operating rooms, a 48-bed intensive care unit and an emergency department that is nearly twice the size of the current one. It is expected to open in 2031. It's still not clear how many new staff will be needed and how many will come over from the Victoria General (VG) Hospital. Hotel rooms required At the construction peak for the QEII Halifax Infirmary project, there will be 850 to 1,000 workers, Volcko said. About two-thirds of those will be from Nova Scotia and the rest will come from out-of-province 'where there's just not sufficient skilled labour.' In response to a question from the NDP and Liberals, Benoit said there are ongoing discussions with Nova Scotia Community College about the void. For those workers coming from away, Volcko said 'there just was not sufficient time to put up a temporary lodging.' He said all 238 rooms at the Atlantica Hotel will be taken up by workers at some point. 'It's expected eventually we'll take over all the rooms and then there will be a tail where we don't need all the rooms again,' he told reporters. He couldn't say how many more rooms may be needed because he's not sure how many workers will be from out of town. 'Our first objective is to employ local talent, local skilled labour,' Volcko said. 'If our peak is in three years, you know, we've got some time to build a workforce.' Karen Oldfield Karen Oldfield, the interim president and CEO of Nova Scotia Health, speaks to reporters after appearing before the province's public accounts committee where healthcare facilities were top of mind. (CTV Atlantic/Callum Smith) For more Nova Scotia news, visit our dedicated provincial page
CBC
an hour ago
- CBC
7 measles cases confirmed in Manitoba during 1st week of June
There were seven confirmed measles cases and four probable cases in the province during first week of June, Manitoba Public Health says. The most current data available, posted Wednesday, only goes to June 7. Altogether, there have been 98 confirmed and eight probable measles cases in the province this year. In May alone, Manitoba reported 72 confirmed and four probable measles cases. Canada's measles outbreak, which began in October 2024, has grown to the point that the country is at risk of losing its measles elimination status — a bar set by the World Health Organization — if the outbreak isn't contained in the coming months. The virus spreads through droplets formed in the air when coughing or sneezing, and an infected person can spread the virus from four days before the measles rash appears until four days after that. Measles symptoms generally appear seven to 21 days after exposure, and may include a fever, runny nose, drowsiness and red eyes. Small white spots can also appear on the inside of the mouth or throat, the province said. Immunization is the only way to protect people from contracting measles, health officials say. The vaccine for measles, mumps, rubella and varicella (chickenpox) is routinely given after kids turn one, with a second shot given at age four to six in Manitoba. If a child is exposed to measles, the second dose can be given earlier. Last week, the province expanded vaccine eligibility to start at six months for children who were evacuated from their communities because of wildfires and who may be staying in southern Manitoba, where there have been measles outbreaks.
CTV News
2 hours ago
- CTV News
Judge denies N.B. auditor general's request to view internal audit reports on travel nurses
A Court of King's Bench justice has denied the New Brunswick auditor general's request to view Vitalité Health Network's internal audit reports on the agency's travel nurse contracts that began in 2022. According to a written decision from Chief Justice Tracey DeWare, the auditor general sought to compel Vitalité to disclose the reports as part of its investigation into the management and use of travel nurses. The decision says Vitalité ordered an internal audit for the period spanning August 2022 to June 2023. 'The Respondent (Vitalité) asserts these internal audits confirmed the existence of deficiencies in the performance of the agency nurses' contract with one of the agencies – Canadian Health Labs ('CHL'),' the decision reads. 'The Respondent and CHL are now involved in litigation arising from this contract. 'The Respondent has refused to produce the internal audit reports on the basis they were properly subject to both a litigation and solicitor-client privilege.' Last year, the auditor general's audit found Vitalité, Horizon Health Network and the Department of Social Development spent $173 million on travel nurse contracts between Jan. 1, 2022 and Feb. 29, 2024. 'The purpose of the audit was to determine if government contracts with private nursing agencies represented good value relative to their costs,' the written decision reads. 'As part of the audit process, the Applicant (auditor general) requested from the Respondent various information and documents. The Applicant was particularly interested in governance practices, policies and billings to the agencies.' Chief Justice DeWare said the auditor general argued section 13 of the Auditor General Act allows them to access documents and information that would otherwise be private or confidential. Vitalité argued the disclosure of the internal audit reports would 'prejudice its ability to prosecute the action against CHL.' Chief Justice DeWare said the court must interpret section 13 of the act restrictively, noting that it does not refer to privileged information. 'While I appreciate the Applicant's argument, the addition of the words 'confidential and private' to section 13 indicates an expanded scope to the information which could be sought, it falls short of explicitly stating an intention to have access to 'privileged' documents,' the decision reads. 'Solicitor-client privilege and litigation privilege are foundational to our legal system. 'Section 13(a) of the Act does not grant the Auditor General the authority to require production of documents or information which are properly subject to a solicitor-client or litigation privilege.' Chief Justice DeWare dismissed the auditor general's application and said Vitalité is entitled to costs, which are fixed at $2,000. For more New Brunswick news, visit our dedicated provincial page.
